Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers -SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert (“Bob”) Doebele, M.D., Ph.D., has been appointed as Chi ...